PROLUNG IS NOW IONIQ SCIENCES

Blog

IONIQ Sciences / News  / IONIQ Sciences announces Dr. Ørjan G. Martinsen has joined its Scientific Advisory Committee

IONIQ Sciences announces Dr. Ørjan G. Martinsen has joined its Scientific Advisory Committee

Salt Lake City, UT, August 17, 2020 – IONIQ Sciences, Inc. (“IONIQ” or the “Company”), is developing an advanced multi-cancer screen for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. Today IONIQ Sciences announced that Dr. Ørjan G. Martinsen has joined its growing Scientific Advisory Committee. Dr. Martinsen is a world-renowned leader in bioimpedance, Editor-in-Chief and co-founder of Journal of Electrical Bioimpedance and past President of the International Society for Electrical Bioimpedance (ISEBI). During the past week, IONIQ Sciences has added two preeminent minds on bioimpedance (Dr. Martinsen and Dr. Sanchez) to its Scientific Advisory Committee. 

Mr. Jared Bauer, IONIQ Sciences CEO, stated, “We are honored to welcome Dr. Martinsen to our Scientific Advisory Committee as we continue our expansion beyond lung cancer into a single screen for multiple cancers. Dr. Martinsen has dedicated his professional endeavors to advancing the field of bioimpedance through leadership positions in a number of global bioimpedance organizations and has been recognized with multiple awards. He has spent twenty years and counting at the University of Oslo advancing the field of bioimpedance. With more than 160 peer-reviewed scientific papers already to his credit, he is quite likely the most prolific contributor to the field of bioimpedance in the world. We are fortunate to have Dr. Martinsen on our growing Scientific Advisory Committee and believe it will serve us well as we actively prepare for the next phase of product development on our mission to commercialize a modern solution for the early detection of multiple cancers.” 

Dr. Martinsen added, “I joined IONIQ’s Scientific Advisory Committee because we share a deep mutual belief in the importance of bioimpedance and health. By sharing my years of hands-on bioimpedance research, I believe it can help propel IONIQ’s Electrical Impedance Analytics technology forward. The ability to detect cancer at its earliest, most-treatable stages when lives can be saved has profound value to society. Together, we will pursue potentially life-saving bioimpedance research with the goal of improving early cancer detection.” 

About IONIQ Sciences, Inc.

IONIQ Sciences, Inc. is developing an advanced multi-cancer screening technology for early detection that has the potential to expand the therapeutic window, dramatically improve survivability and reduce the cost of healthcare. IONIQ Sciences operates at the confluence of its Electrical Impedance Analytics (EIA) technology and Artificial Intelligence (AI). IONIQ Science’s first product utilizing its proprietary analytic platform, the IONIQ ProLung Test™ for lung cancer, has been designated a Breakthrough Device by the U.S. FDA. ProLung rebranded to IONIQ Sciences in May 2020. 

Forward-Looking Statements
Statements contained in this release that are not purely historical, including, without limitation statements regarding IONIQ Sciences’ future performance and goals, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties such as those described in the IONIQ Sciences’ Annual Report on Form 10-K for the year ended December 31, 2017 and subsequent filings with the Securities and Exchange Commission. Such risks and uncertainties include inherent risks and uncertainties relating to IONIQ Sciences’ ability to meet its funding requirements for its operations and other commitments and to obtain successful test results and regulatory approvals for its products. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections.

For further information about IONIQ Sciences, Inc., please contact:
Andy Robertson | 1-801-503-9231| acr@IONIQsciences.com
IONIQ Sciences, Inc., Vice President of Business Development

IONIQ Sciences, Inc.
350 W. 800 N., Suite 214
Salt Lake City, Utah 84103
USA
www.IONIQsciences.com

Follow IONIQ Sciences, Inc. on Twitter, Facebook and LinkedIn: @IONIQSciences